Compartilhar
Informação da revista
Vol. 46. Núm. S4.
HEMO 2024
Páginas S306 (outubro 2024)
Vol. 46. Núm. S4.
HEMO 2024
Páginas S306 (outubro 2024)
LEUCEMIA LINFOIDE CRÔNICA E OUTRAS DOENÇAS LINFOPROLIFERATIVAS CRÔNICAS
Acesso de texto completo
SYSTEMATIC REVIEW AND META-ANALYSIS OF PHASE I AND II CLINICAL TRIALS: SAFETY AND EFFICACY OF ANTI-CD19 CAR-T CELL THERAPY IN COMBINATION WITH BRUTON'S TYROSINE KINASE INHIBITORS (BTKI) FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Visitas
369
KAM Martinsa, IC Fariaa, LJC Cardosob, MS Ramosa, ELO Pintoa, FS Barbosaa, JAM Souzaa, VC Soaresa, MM Corcinioc, MY Ferreirad
a Centro Universitário de Belo Horizonte (UniBH), Belo Horizonte, Brazil
b Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil
c Universidade Tiradentes (UNIT), Aracaju, Brazil
d Universidade Nove de Julho (UNINOVE), São Paulo, Brazil
Este item recebeu
Informação do artigo
Suplemento especial
Este artigo faz parte de:
Vol. 46. Núm S4

HEMO 2024

Mais dados
Objective

Chronic lymphocytic leukemia (CLL) presents a variable evolution history, resulting in different treatment outcomes due to disease progression in lymph nodes, organs, or bone marrow. Complete Remission (CR) is rare, and the majority of patients experience disease recurrence after standard treatment. Recent studies portray the use of chimeric antigen receptor T (CAR-T) cells as promising in this area. Thus, the aim of the present study is to conduct a systematic review and meta-analysis evaluating the safety and efficacy of CAR-T cell immunotherapy concomitant with the use of Bruton tyrosine kinase inhibitors (BTKi) in relapsed/refractory (R/R) CLL.

Methods

PubMed, Embase, Web of Science, and Cochrane databases were searched for trials published up to January 9, 2024. We included studies that reported outcomes from patients with R/R CLL who underwent CD19 CAR T-cell immunotherapy and received ibrutinib before, during, and after infusion. We used single proportion analysis with 95% confidence intervals under a random-effects model and heterogeneity was examined with the Cochran Q test and I(2) statistics. Endpoints were related to safety (prevalence of adverse events) and efficacy of the treatment (complete response rate, minimal residual disease, overall survival and progression-free survival).

Results

Four studies were included, comprising phase I and II clinical trials, involving 62 patients aged between 40 and 77 years with R/R CLL who underwent CAR-T cell immunotherapy targeting CD19 concurrently with ibrutinib. The prevalence of Cytokine Release Syndrome (CRS) grades III and IV was 5.12% (95% CI 0.00 -12.54; p = 0.25), while that of neurotoxicity was 37.13% (95% CI 17.22-57.05; p = 0.05), with a predominance of grade III cases. The Complete Remission (CR) rate was 36.8% (95% CI 22.32-51.29; p = 0.34), and the prevalence of undetectable Minimal Residual Disease (MRD) was 68.2% (95% CI 41.87-94.52; p < 0.01). In studies reporting patients’ overall survival (OS) rate at 1 year, it was 82.76% (95% CI 63.47-100.00; p = 0.06), and the progression-free survival (PFS) rate at 1 year was 64.2% (95% CI; 31.42 - 96.99; p < 0.01). Significant results were revealed in the analyses of PFS, MRD, and OS, suggesting a potential real efficacy in improving the survival of CLL patients.

Discussion

The safety profile of CAR-T cell therapy with BTK inhibitors in R/R CLL patients appears manageable, with a low prevalence of severe CRS but a relatively higher occurrence of grade III neurotoxicity. However, the efficacy outcomes are promising, with a significant CR rate of 36.8% and a high prevalence of undetectable MRD at 68.2%. Additionally, the one-year OS and PFS rates of 82.76% and 64.2%, respectively, highlight the potential clinical benefit of this combination therapy. While acknowledging the study's limitations, including sample size, heterogeneity, and phase 1 and 2 trials, these promising findings support the potential feasibility of CAR-T cell therapy with BTK inhibitors in R/R CLL.

Conclusion

These findings indicate a reduction in disease progression, highlighting the potential clinical benefit of this approach. They suggest that CAR-T cell therapy in combination with BTK inhibitors is well tolerated and may increase survival and prevent disease progression in patients with R/R CLL. However, continuing current clinical trials with larger samples is necessary to further validate the results presented in this study with greater reliability.

O texto completo está disponível em PDF
Baixar PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas